1
|
Pinzi L, Conze C, Bisi N, Torre GD, Soliman A, Monteiro-Abreu N, Trushina NI, Krusenbaum A, Dolouei MK, Hellwig A, Christodoulou MS, Passarella D, Bakota L, Rastelli G, Brandt R. Quantitative live cell imaging of a tauopathy model enables the identification of a polypharmacological drug candidate that restores physiological microtubule interaction. Nat Commun 2024; 15:1679. [PMID: 38396035 PMCID: PMC10891143 DOI: 10.1038/s41467-024-45851-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 02/06/2024] [Indexed: 02/25/2024] Open
Abstract
Tauopathies such as Alzheimer's disease are characterized by aggregation and increased phosphorylation of the microtubule-associated protein tau. Tau's pathological changes are closely linked to neurodegeneration, making tau a prime candidate for intervention. We developed an approach to monitor pathological changes of aggregation-prone human tau in living neurons. We identified 2-phenyloxazole (PHOX) derivatives as putative polypharmacological small molecules that interact with tau and modulate tau kinases. We found that PHOX15 inhibits tau aggregation, restores tau's physiological microtubule interaction, and reduces tau phosphorylation at disease-relevant sites. Molecular dynamics simulations highlight cryptic channel-like pockets crossing tau protofilaments and suggest that PHOX15 binding reduces the protofilament's ability to adopt a PHF-like conformation by modifying a key glycine triad. Our data demonstrate that live-cell imaging of a tauopathy model enables screening of compounds that modulate tau-microtubule interaction and allows identification of a promising polypharmacological drug candidate that simultaneously inhibits tau aggregation and reduces tau phosphorylation.
Collapse
Affiliation(s)
- Luca Pinzi
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Christian Conze
- Department of Neurobiology, School of Biology/Chemistry, Osnabrück University, Osnabrück, Germany
| | - Nicolo Bisi
- Department of Neurobiology, School of Biology/Chemistry, Osnabrück University, Osnabrück, Germany
| | - Gabriele Dalla Torre
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
- Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK
| | - Ahmed Soliman
- Department of Neurobiology, School of Biology/Chemistry, Osnabrück University, Osnabrück, Germany
| | - Nanci Monteiro-Abreu
- Department of Neurobiology, School of Biology/Chemistry, Osnabrück University, Osnabrück, Germany
| | - Nataliya I Trushina
- Department of Neurobiology, School of Biology/Chemistry, Osnabrück University, Osnabrück, Germany
| | - Andrea Krusenbaum
- Department of Neurobiology, School of Biology/Chemistry, Osnabrück University, Osnabrück, Germany
| | - Maryam Khodaei Dolouei
- Department of Neurobiology, School of Biology/Chemistry, Osnabrück University, Osnabrück, Germany
| | - Andrea Hellwig
- Department of Neurobiology, Interdisciplinary Center for Neurosciences, Heidelberg University, Heidelberg, Germany
| | - Michael S Christodoulou
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
- Department of Chemistry, University of Milan, Milan, Italy
- Department of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, Milan, Italy
| | | | - Lidia Bakota
- Department of Neurobiology, School of Biology/Chemistry, Osnabrück University, Osnabrück, Germany
| | - Giulio Rastelli
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
| | - Roland Brandt
- Department of Neurobiology, School of Biology/Chemistry, Osnabrück University, Osnabrück, Germany.
- Center for Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany.
- Institute of Cognitive Science, Osnabrück University, Osnabrück, Germany.
| |
Collapse
|
2
|
Abstract
Proper elucidation of drug-target interaction is one of the most significant steps at the early stages of the drug development research. Computer-aided drug design tools have substantial contribution to this stage. In this chapter, we specifically concentrate on the computational methods widely used to develop reversible inhibitors for monoamine oxidase (MAO) isozymes. In this context, current computational techniques in identifying the best drug candidates showing high potency are discussed. The protocols of structure-based drug design methodologies, namely, molecular docking, in silico screening, and molecular dynamics simulations, are presented. Employing case studies of safinamide binding to MAO B, we demonstrate how to use AutoDock 4.2.6 and NAMD software packages.
Collapse
Affiliation(s)
- Kemal Yelekçi
- Department of Bioinformatics and Genetics, Faculty of Engineering and Natural Sciences, Kadir Has University, Istanbul, Turkey.
| | - Safiye Sağ Erdem
- Department of Chemistry, Faculty of Arts and Sciences, Marmara University, Istanbul, Turkey
| |
Collapse
|
3
|
Rastelli G. Meet the Editorial Board Member. Curr Med Chem 2022. [DOI: 10.2174/092986732915220411100429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Giulio Rastelli
- Department of Life Sciences
University of Modena and Reggio Emilia
Modena
Italy
| |
Collapse
|
4
|
Iacovino LG, Pinzi L, Facchetti G, Bortolini B, Christodoulou MS, Binda C, Rastelli G, Rimoldi I, Passarella D, Di Paolo ML, Dalla Via L. Promising Non-cytotoxic Monosubstituted Chalcones to Target Monoamine Oxidase-B. ACS Med Chem Lett 2021; 12:1151-1158. [PMID: 34262643 PMCID: PMC8274062 DOI: 10.1021/acsmedchemlett.1c00238] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Accepted: 06/09/2021] [Indexed: 12/24/2022] Open
Abstract
A library of monosubstituted chalcones (1-17) bearing electron-donating and electron-withdrawing groups on both aromatic rings were selected. The cell viability on human tumor cell lines was evaluated first. The compounds unable to induce detectable cytotoxicity (1, 13, and 14) were tested using the monoamine oxidase (MAO) activity assay. Interestingly, they inhibit MAO-B, acting as competitive inhibitors, with 13 and 14 showing the best profiles. In particular, 13 exhibited a potency higher than that of safinamide, taken as a reference. Docking studies and crystallographic analysis showed that in human MAO-B 13 binds with the halogen-substituted aromatic ring in the entrance cavity, similar to safinamide, whereas 14 is accommodated in the opposite way. The main conclusion of this cell biology, biochemistry, and structural study is to highlights 13 as a chalcone derivative that is worth consideration for the development of novel MAO-B-selective inhibitors for the treatment of neurodegenerative diseases.
Collapse
Affiliation(s)
- Luca G. Iacovino
- Dipartimento
di Biologia e Biotecnologie, Università
di Pavia, Pavia 27100, Italy
| | - Luca Pinzi
- Dipartimento
di Scienze della Vita, Università
degli Studi di Modena e Reggio Emilia, Modena 41125, Italy
| | - Giorgio Facchetti
- DISFARM,
Sezione di Chimica Generale e Organica “A. Marchesini”, Università degli Studi di Milano, Milano 20133, Italy
| | - Beatrice Bortolini
- Dipartimento
di Scienze del Farmaco, Università
degli Studi di Padova, Padova 35131, Italy
| | - Michael S. Christodoulou
- DISFARM,
Sezione di Chimica Generale e Organica “A. Marchesini”, Università degli Studi di Milano, Milano 20133, Italy
| | - Claudia Binda
- Dipartimento
di Biologia e Biotecnologie, Università
di Pavia, Pavia 27100, Italy
| | - Giulio Rastelli
- Dipartimento
di Scienze della Vita, Università
degli Studi di Modena e Reggio Emilia, Modena 41125, Italy
| | - Isabella Rimoldi
- DISFARM,
Sezione di Chimica Generale e Organica “A. Marchesini”, Università degli Studi di Milano, Milano 20133, Italy
| | - Daniele Passarella
- Dipartimento
di Chimica, Università degli Studi
di Milano, Milano 20133, Italy
| | - Maria Luisa Di Paolo
- Dipartimento
di Medicina Molecolare, Università
degli Studi di Padova, Padova 35131, Italy
| | - Lisa Dalla Via
- Dipartimento
di Scienze del Farmaco, Università
degli Studi di Padova, Padova 35131, Italy
| |
Collapse
|
5
|
Rastelli G. Meet Our Editorial Board Member. Curr Med Chem 2021. [DOI: 10.2174/092986732815210505120530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Giulio Rastelli
- Department of Life Sciences University of Modena and Reggio Emilia Modena,Italy
| |
Collapse
|
6
|
Sağlık BN, Kaya Çavuşoğlu B, Acar Çevik U, Osmaniye D, Levent S, Özkay Y, Kaplancıklı ZA. Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling. RSC Med Chem 2020; 11:1063-1074. [PMID: 33479699 DOI: 10.1039/d0md00150c] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Accepted: 07/24/2020] [Indexed: 01/30/2023] Open
Abstract
Monoamine oxidases (MAOs) are important drug targets for the management of neurological disorders. Herein, a series of new 1,3,4-thiadiazole derivatives bearing various alkyl/arylamine moieties as MAO inhibitors were designed and synthesized. All of the compounds were more selective against hMAO-A than hMAO-B. The half maximal inhibitory concentration (IC50) values of most of the compounds were lower than that of the common drug moclobemide (IC50 = 4.664 μM) and compound 6b was proven to be the most active compound (IC50 = 0.060 μM). Moreover, it was seen that compound 6b showed a similar inhibition profile to that of clorgyline (IC50 = 0.048 μM). The inhibition profile was found to be reversible and competitive for compound 6b with MAO-A selectivity. Molecular modelling studies aided in the understanding of the interaction modes between compound 6b and MAO-A. Furthermore, this compound was predicted to have a good pharmacokinetic profile and high BBB penetration. Therefore, such compounds are of interest towards developing new MAO inhibitors.
Collapse
Affiliation(s)
- Begüm Nurpelin Sağlık
- Department of Pharmaceutical Chemistry , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey.,Doping and Narcotic Compounds Analysis Laboratory , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey
| | - Betül Kaya Çavuşoğlu
- Doping and Narcotic Compounds Analysis Laboratory , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey.,Department of Pharmaceutical Chemistry , Faculty of Pharmacy , Bulent Ecevit University , 67600 Zonguldak , Turkey . ; ; Tel: +90 (372) 261 31 54
| | - Ulviye Acar Çevik
- Department of Pharmaceutical Chemistry , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey.,Doping and Narcotic Compounds Analysis Laboratory , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey
| | - Derya Osmaniye
- Department of Pharmaceutical Chemistry , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey.,Doping and Narcotic Compounds Analysis Laboratory , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey
| | - Serkan Levent
- Department of Pharmaceutical Chemistry , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey.,Doping and Narcotic Compounds Analysis Laboratory , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey
| | - Yusuf Özkay
- Department of Pharmaceutical Chemistry , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey.,Doping and Narcotic Compounds Analysis Laboratory , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey
| | - Zafer Asım Kaplancıklı
- Department of Pharmaceutical Chemistry , Faculty of Pharmacy , Anadolu University , Eskişehir , Turkey
| |
Collapse
|
7
|
Matos MJ, Herrera Ibatá DM, Uriarte E, Viña D. Coumarin-Rasagiline Hybrids as Potent and Selective hMAO-B Inhibitors, Antioxidants, and Neuroprotective Agents. ChemMedChem 2020; 15:532-538. [PMID: 32037726 DOI: 10.1002/cmdc.202000018] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 02/06/2020] [Indexed: 01/26/2023]
Abstract
The frequency, complexity and morbidity of neurodegenerative diseases make them a great challenge for nowadays medicine. Most of the treatments currently used for Parkinson's disease - the second most prevalent - are only symptomatic. Therefore, it is urgent to develop drugs that are able to act simultaneously on different targets, being able to stop neuronal death and promote the recovery of neuronal populations already affected. In this work, we studied the activity of a series of hybrid molecules, which combine the structure of both coumarin and an alkynylamine group inspired on rasagiline, as MAO inhibitors, antioxidants and neuroprotective agents. Half of the studied hybrids turned out to be selective monoamine oxidase B (hMAO-B) inhibitors in the low micro/nanomolar range, demonstrating that positions 3 (compounds 1-3) and 7 (compounds 8 and 10) of the coumarin scaffold are the most suitable for the incorporation of the alkynylamine chain. All the studied compounds proved to be capable of neutralizing free radicals (DPPH). Finally, the 4-(but-2-yn-1-ylamino)coumarin (5) showed neuroprotective effects on glial cells and the 4-methyl-7-(pent-2-yn-1-ylamino)coumarin (8) inhibited intraneuronal ROS production as well.
Collapse
Affiliation(s)
- Maria J Matos
- CIQUP/Department of Chemistry and Biochemistry Faculty of Sciences, University of Porto, 4169-007, Porto, Portugal.,Departamento de Química Orgánica Facultad de Farmacia, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Diana M Herrera Ibatá
- Chronic Diseases Pharmacology Group Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Eugenio Uriarte
- Departamento de Química Orgánica Facultad de Farmacia, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain.,Instituto de Ciencias Químicas Aplicadas, Universidad Autónoma de Chile, 7500912, Santiago, Chile
| | - Dolores Viña
- Chronic Diseases Pharmacology Group Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain
| |
Collapse
|